A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
This application is the U.S. national phase of International Patent Application No. PCT/US2003/023290, which was filed on Jul. 24, 2003, and which claims the benefit of U.S. Provisional Patent Application No. 60/398,092, which was filed on Jul. 24, 2002.
